• HUTCHMED received FDA orphan drug designation for sovleplenib to treat autoimmune hemolytic anemia.
• The designation offers eligibility for seven years of US market exclusivity upon approval, alongside development incentives.
• This is sovleplenib’s second FDA orphan designation, following primary immune thrombocytopenia in October 2026.
• Chinese applications for primary immune thrombocytopenia and warm autoimmune hemolytic anemia remain under National Medical Products Administration review.
• The pivotal ESLIM-01 and ESLIM-02 trials in China have already produced positive results supporting those applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041900PRIMZONEFULLFEED9870656) on November 05, 2026, and is solely responsible for the information contained therein.